Shionogi Still Hopeful For Xocova In US Despite Phase III Fail

Missed Primary Endpoints

 
• By Lisa Takagi

Despite sales success in Japan and a fast track designation in the US, Shionogi’s oral COVID-19 therapeutic has missed statistical significance in a global Phase III trial in patients with mild to moderate symptoms.

Shionogi's Xocova faced a thick wall of P3 failure before its NDA filing in the US after a huge commercial success in Japan.
Xocova faces US Phase Phase III failure after commercial success in Japan • Source: Shutterstock

More from Clinical Trials

More from R&D